Oral pazopanib improves sight in macular degeneration

Oral pazopanib (Glaxo’s kidney cancer drug Votrient) is well tolerated and improves mean best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29 in a small, per-protocol, non-rescued population of patients with age-related macular degeneration (AMD), according to a study published online Oct. 10 in JAMA Ophthalmology.

For more info:  http://medicalxpress.com/news/2013-10-oral-pazopanib-sight-macular-degeneration.html

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: